ARVO 2023

START-END Apr 25, 2023 from 9:45 AM to 11:45 AM EDT

Title: A Phase 1b/2 Study of the Safety and Tolerability of Tinlarebant in Adolescent Patients Affected by Stargardt Disease – 18-Month Data
Presenter: Dr. John R Grigg (The University of Sydney Save Sight Institute, The Children's Hospital at Westmead)
Location: The New Orleans Ernest N. Morial Convention Center (Hall B - Exhibits and Posters)
Posterboard Number: 2597 - B0310
Session: Retina/RPE: New drugs, mechanisms of action and toxicity
Session Number: 320

Supporting Materials

Join our mailing list.


Sign up to receive important updates and news from Belite Bio